Core Points - Telomir Pharmaceuticals has appointed Erez Aminov as the new CEO and Chairman of the Board following the passing of the previous Chairman and CEO, Dr. Christopher Chapman, Jr. [1][2] - The company is focused on developing Telomir-1, a novel small molecule aimed at promoting longevity by lengthening telomeres, which are protective caps on chromosomes [5]. Management Changes - Erez Aminov, previously the CEO of MIRA Pharmaceuticals, has taken over leadership roles at Telomir [2]. - Three directors have resigned from the Board to support the new management, with three new directors appointed: Dr. Matthew P. Del Giudice, Mr. Ned MacPherson, and Matthew Pratt Whalen, CPA [3]. - Current directors Dr. Craig Eagle and Michael Jerman will remain on the Board [3]. Company Overview - Telomir Pharmaceuticals is in the pre-clinical stage, focusing on Telomir-1 to address age-related conditions in both humans and dogs [5]. - The company aims to enhance quality of life by potentially preventing degenerative diseases associated with aging through its drug candidate [5].
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman